TY - JOUR
T1 - Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action
AU - Palte, Rachel L.
AU - Juan, Veronica
AU - Gomez-Llorente, Yacob
AU - Bailly, Marc Andre
AU - Chakravarthy, Kalyan
AU - Chen, Xun
AU - Cipriano, Daniel
AU - Fayadat-Dilman, Laurence
AU - Gathiaka, Symon
AU - Greb, Heiko
AU - Hall, Brian
AU - Handa, Mas
AU - Hsieh, Mark
AU - Kofman, Esther
AU - Lin, Heping
AU - Miller, J. Richard
AU - Nguyen, Nhung
AU - O’Neil, Jennifer
AU - Shaheen, Hussam
AU - Sterner, Eric
AU - Strickland, Corey
AU - Sun, Angie
AU - Taremi, Shane
AU - Scapin, Giovanna
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Human Arginase 1 (hArg1) is a metalloenzyme that catalyzes the hydrolysis of l-arginine to l-ornithine and urea, and modulates T-cell-mediated immune response. Arginase-targeted therapies have been pursued across several disease areas including immunology, oncology, nervous system dysfunction, and cardiovascular dysfunction and diseases. Currently, all published hArg1 inhibitors are small molecules usually less than 350 Da in size. Here we report the cryo-electron microscopy structures of potent and inhibitory anti-hArg antibodies bound to hArg1 which form distinct macromolecular complexes that are greater than 650 kDa. With local resolutions of 3.5 Å or better we unambiguously mapped epitopes and paratopes for all five antibodies and determined that the antibodies act through orthosteric and allosteric mechanisms. These hArg1:antibody complexes present an alternative mechanism to inhibit hArg1 activity and highlight the ability to utilize antibodies as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general.
AB - Human Arginase 1 (hArg1) is a metalloenzyme that catalyzes the hydrolysis of l-arginine to l-ornithine and urea, and modulates T-cell-mediated immune response. Arginase-targeted therapies have been pursued across several disease areas including immunology, oncology, nervous system dysfunction, and cardiovascular dysfunction and diseases. Currently, all published hArg1 inhibitors are small molecules usually less than 350 Da in size. Here we report the cryo-electron microscopy structures of potent and inhibitory anti-hArg antibodies bound to hArg1 which form distinct macromolecular complexes that are greater than 650 kDa. With local resolutions of 3.5 Å or better we unambiguously mapped epitopes and paratopes for all five antibodies and determined that the antibodies act through orthosteric and allosteric mechanisms. These hArg1:antibody complexes present an alternative mechanism to inhibit hArg1 activity and highlight the ability to utilize antibodies as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general.
UR - http://www.scopus.com/inward/record.url?scp=85111518865&partnerID=8YFLogxK
U2 - 10.1038/s42003-021-02444-z
DO - 10.1038/s42003-021-02444-z
M3 - Article
C2 - 34326456
AN - SCOPUS:85111518865
SN - 2399-3642
VL - 4
JO - Communications Biology
JF - Communications Biology
IS - 1
M1 - 927
ER -